It looks promising for overian cancer suffers it appears that glaxo has a drug in phase 1 clinical trials its a biopharmaceutical called iboctadekin† + Doxil its a IL18 immunomodulator + topoisomerase ll inhibitor and has been indicated for ovarian cancer.As it is still in phase 1 in clinical trials it has a long way to go, about 7 years or so.....
No comments:
Post a Comment